Desire Collen
39Patents
10h-index
22Co-inventors
75Inventor score
Filing activity: Mar 1, 1977 → Feb 3, 2014
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US6309888A | Detection and determination of the stages of coronary artery disease | Emerging Cross-Sectional Technologies | 43 | Expired |
| US5951980A | Identification, production and use of new staphylokinase derivatives with reduced immunogenicity | Human Necessities | 26 | Expired |
| US4752603A | Plasminogen activator and pharmaceutical composition having thrombolytic activity | Emerging Cross-Sectional Technologies | 24 | Expired |
| US6727102B1 | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins | Emerging Cross-Sectional Technologies | 21 | Expired |
| US6398757B1 | Gene therapeutic treatment of blood vessel associated disorders | Human Necessities | 19 | Expired |
| US7357929B2 | Placental growth factor as a target for the treatment of osteoporosis | Chemistry; Metallurgy | 18 | Expired |
| US6946438B1 | Use of compounds that reduce alpha2-antiplasmin in vivo for the preparation of a composition for the treatment of ischemic stroke | Chemistry; Metallurgy | 12 | Expired |
| US4198335A | Antiplasmin and antiserum | Emerging Cross-Sectional Technologies | 11 | Expired |
| US5275812A | Method of treatment for myocardial infarction | Human Necessities | 10 | Expired |
| US4202872A | Determination of heparin in blood plasma | Emerging Cross-Sectional Technologies | 10 | Expired |
| US4346029A | Antiplasmin and antiserum | Emerging Cross-Sectional Technologies | 8 | Expired |
| US7166469B2 | Detection and determination of the stages of coronary artery disease | Emerging Cross-Sectional Technologies | 7 | Expired |
| US4216291A | Thrombosis-test | Emerging Cross-Sectional Technologies | 7 | Expired |
| US4623718A | Novel composition of matter of antithrombin III bound to a heparin fragment | Chemistry; Metallurgy | 6 | Expired |
| US7229776B2 | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins | Emerging Cross-Sectional Technologies | 6 | Expired |
| US7226908B2 | Use of VEGF and homologues to treat neuron disorders | Chemistry; Metallurgy | 6 | Expired |
| US7229775B2 | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins | Emerging Cross-Sectional Technologies | 5 | Expired |
| US7482004B2 | Inhibitors of placental growth factor for the treatment of pathological angiogenesis, pathological arteriogenesis, inflammation, tumor formation and/or vascular leakage | Physics | 5 | Expired |
| US7445775B2 | Yeast expression vector and a method of making a recombinant protein by expression in a yeast cell | Chemistry; Metallurgy | 5 | Expired |
| US5336495A | Use of staphylokinase for the preparation of a pharmaceutical composition for treating arterial thromboisi | Human Necessities | 4 | Expired |
| US7875704B2 | Anti-PLGF antibody | Chemistry; Metallurgy | 4 | Active |
| US7709450B2 | Stimulation of vascularization with VEGF-B-186 | Chemistry; Metallurgy | 4 | Expired |
| US7390627B2 | Assays, antibodies, and standards for detection of oxidized and MDA-modified low density lipoproteins | Emerging Cross-Sectional Technologies | 4 | Active |
| US7592314B2 | Use of VEGF and homologues to treat neuron disorders | Chemistry; Metallurgy | 3 | Active |
| US6383483B1 | Staphylokinase derivatives with cysteine substitutions | Human Necessities | 3 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.